

# Dirk BÄhmer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2052967/publications.pdf>

Version: 2024-02-01

62  
papers

2,312  
citations

236925

25  
h-index

214800

47  
g-index

81  
all docs

81  
docs citations

81  
times ranked

2882  
citing authors

#	ARTICLE	IF	CITATIONS
1	Thymidine phosphorylase induction by ionizing radiation antagonizes 5-fluorouracil resistance in human ductal pancreatic adenocarcinoma. <i>Radiation and Environmental Biophysics</i> , 2022, , 1.	1.4	0
2	Salvage Radiotherapy versus Observation for Biochemical Recurrence following Radical Prostatectomy for Prostate Cancer: A Matched Pair Analysis. <i>Cancers</i> , 2022, 14, 740.	3.7	5
3	Impact of Dose Escalation on the Efficacy of Salvage Radiotherapy for Recurrent Prostate Cancerâ€”A Risk-Adjusted, Matched-Pair Analysis. <i>Cancers</i> , 2022, 14, 1320.	3.7	5
4	Lead-time bias does not falsify the efficacy of early salvage radiotherapy for recurrent prostate cancer. <i>Radiotherapy and Oncology</i> , 2021, 154, 255-259.	0.6	6
5	Ultrahypofractionation of localized prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 89-96.	2.0	22
6	Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy. <i>European Urology Oncology</i> , 2021, 4, 301-304.	5.4	2
7	Lacking Evidence to Recommend Neoadjuvant Chemotherapy and Definitive Radiotherapy in Muscle-Invasive Bladder Cancer. <i>Current Oncology Reports</i> , 2021, 23, 18.	4.0	2
8	Radiotherapy in nodal oligorecurrent prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 575-580.	2.0	11
9	FDG-PET/CT for pretherapeutic lymph node staging in non-small cell lung cancer: A tailored approach to the ESTS/ESMO guideline workflow. <i>Lung Cancer</i> , 2021, 157, 66-74.	2.0	6
10	Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death. <i>Journal of Clinical Oncology</i> , 2021, 39, 2284-2293.	1.6	54
11	Moderately hypofractionated radiotherapy as definitive treatment for localized prostate cancer: Pattern of practice in German-speaking countries. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 993-1000.	2.0	3
12	Validation of Independent Prognostic Value of Asphericity of 18F-Fluorodeoxyglucose Uptake in Nonâ€”Small-Cell Lung Cancer Patients Undergoing Treatment With Curative Intent. <i>Clinical Lung Cancer</i> , 2020, 21, 264-272.e6.	2.6	3
13	Role of combined radiation and androgen deprivation therapy in intermediate-risk prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 109-116.	2.0	14
14	Reirradiation of High-Grade Gliomas: A Retrospective Analysis of 198 Patients Based on the CharitÃ© Data Set. <i>Advances in Radiation Oncology</i> , 2020, 5, 959-964.	1.2	7
15	Need for Androgen Deprivation Therapy in Addition to Definitive Radiation Therapy in Patients With Intermediate-Risk Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1746-1746.	1.6	1
16	Side effects of proton beam therapy of choroidal melanoma in dependence of the dose to the optic disc and the irradiated length of the optic nerve. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , 2020, 258, 2523-2533.	1.9	5
17	Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 589-597.	2.0	10
18	The impact of <sc>prostateâ€”specific antigen</sc> persistence after radical prostatectomy on the efficacy of salvage radiotherapy in patients with primary NO prostate cancer. <i>BJU International</i> , 2019, 124, 785-791.	2.5	20

#	ARTICLE	IF	CITATIONS
19	Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study. <i>European Urology</i> , 2019, 76, 443-449.	1.9	14
20	Impact of bladder volume on acute genitourinary toxicity in intensity modulated radiotherapy for localized and locally advanced prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 517-525.	2.0	18
21	Effect of early salvage radiotherapy at PSA $\leq 0.5$ ng/ml and impact of post-SRT PSA nadir in post-prostatectomy recurrent prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 344-349.	3.9	17
22	Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 619-626.	2.0	26
23	Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival. <i>Acta Oncologica</i> , 2018, 57, 362-367.	1.8	28
24	Local ablative treatment for synchronous single organ oligometastatic lung cancer – A propensity score analysis of 180 patients. <i>Lung Cancer</i> , 2018, 125, 164-173.	2.0	27
25	Defining biochemical recurrence after radical prostatectomy and timing of early salvage radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 692-699.	2.0	19
26	Dosimetric implications of inter- and intrafractional prostate positioning errors during tomotherapy. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 700-706.	2.0	25
27	Hypofractionated radiotherapy for localized prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 1-12.	2.0	40
28	Radiotherapy and Hormone Treatment in Prostate Cancer. <i>Deutsches Arzteblatt International</i> , 2016, 113, 235-41.	0.9	9
29	Cataract development in patients treated with proton beam therapy for uveal melanoma. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2016, 254, 1625-1630.	1.9	17
30	Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991. <i>Journal of Clinical Oncology</i> , 2016, 34, 1748-1756.	1.6	182
31	In Reply. <i>Deutsches Arzteblatt International</i> , 2016, 113, 678-679.	0.9	0
32	Severe radiotoxicity in an allogeneic transplant recipient with a heterozygous <i>ATM</i> mutation. <i>European Journal of Haematology</i> , 2015, 95, 90-92.	2.2	6
33	Results for local control and functional outcome after linac-based image-guided stereotactic radiosurgery in 190 patients with vestibular schwannoma. <i>Journal of Radiation Research</i> , 2014, 55, 288-292.	1.6	25
34	Protection of quality and innovation in radiation oncology: The prospective multicenter trial the German Society of Radiation Oncology (DEGRO-QUIRO study). <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 433-443.	2.0	46
35	Image-guided intensity-modulated radiotherapy for patients with locally advanced gastric cancer: a clinical feasibility study. <i>Gastric Cancer</i> , 2014, 17, 537-541.	5.3	4
36	Current standards and future directions for prostate cancer radiation therapy. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 75-88.	2.4	13

#	ARTICLE	IF	CITATIONS
37	Oligometastases: the new paradigm and options for radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2013, 189, 357-363.	2.0	23
38	Use of EORTC Target Definition Guidelines for Dose-Intensified Salvage Radiation Therapy for Recurrent Prostate Cancer: Results of the Quality Assurance Program of the Randomized Trial SAKK 09/10. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 534-541.	0.8	23
39	The impact of patient compliance with adjuvant radiotherapy: a comprehensive cohort study. <i>Cancer Medicine</i> , 2013, 2, 712-717.	2.8	27
40	A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study. <i>Annals of Oncology</i> , 2012, 23, 2259-2264.	1.2	34
41	Interfraction rotation of the prostate as evaluated by kilovoltage X-ray fiducial marker imaging in intensity-modulated radiotherapy of localized prostate cancer. <i>Medical Dosimetry</i> , 2012, 37, 396-400.	0.9	28
42	Randomized Phase III Trial of Sequential Adjuvant Chemoradiotherapy With or Without Erythropoietin Alfa in Patients With High-Risk Cervical Cancer: Results of the NOGGO-AGO Intergroup Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 3791-3797.	1.6	41
43	Residual Translational and Rotational Errors after kV X-Ray Image-Guided Correction of Prostate Location Using Implanted Fiducials. <i>Strahlentherapie Und Onkologie</i> , 2010, 186, 544-550.	2.0	24
44	The German S3 Guideline Prostate Cancer. <i>Strahlentherapie Und Onkologie</i> , 2010, 186, 531-534.	2.0	26
45	Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study. <i>Annals of Oncology</i> , 2010, 21, 2201-2205.	1.2	41
46	MRI before and after external beam intensity-modulated radiotherapy of patients with prostate cancer: The feasibility of monitoring of radiation-induced tissue changes using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence. <i>Radiotherapy and Oncology</i> , 2009, 93, 241-245.	0.6	38
47	Postimplantation Analysis Enables Improvement of Dose-Volume Histograms and Reduction of Toxicity for Permanent Seed Implantation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 28-35.	0.8	11
48	Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. <i>Radiotherapy and Oncology</i> , 2007, 84, 121-127.	0.6	272
49	Magnetic nanoparticles for interstitial thermotherapy – feasibility, tolerance and achieved temperatures. <i>International Journal of Hyperthermia</i> , 2006, 22, 673-685.	2.5	243
50	Guidelines for primary radiotherapy of patients with prostate cancer. <i>Radiotherapy and Oncology</i> , 2006, 79, 259-269.	0.6	139
51	Radiochemotherapy combined with regional pelvic hyperthermia induces high response and resectability rates in patients with nonresectable cervical cancer – FIGO IIB bulky. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 1159-1167.	0.8	26
52	Influence of Organ at Risk Definition on Rectal Dose-Volume Histograms in Patients with Prostate Cancer Undergoing External-Beam Radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2006, 182, 277-282.	2.0	22
53	High Dose Rate (HDR) Brachytherapy with Conformal Radiation Therapy for Localized Prostate Cancer. <i>European Urology</i> , 2005, 47, 441-448.	1.9	69
54	Testicular Dose in Prostate Cancer Radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2005, 181, 179-184.	2.0	35

#	ARTICLE	IF	CITATIONS
55	Thermoradiotherapy Using Interstitial Self-Regulating Thermoseeds: An Intermediate Analysis of a Phase II Trial. <i>European Urology</i> , 2004, 45, 574-580.	1.9	34
56	Interstitial Hyperthermia Using Thermoseeds in Combination with Conformal Radiotherapy for Localized Prostate Cancer. , 2002, 36, 171-176.		3
57	High-Dose Rate Brachytherapy - The Charité½ Experience. , 2002, 36, 177-182.		0
58	High Dose Rate Brachytherapy of Localized Prostate Cancer. <i>European Urology</i> , 2002, 41, 420-426.	1.9	49
59	Interstitial Hyperthermia using Self-Regulating Thermoseeds Combined with Conformal Radiation Therapy. <i>European Urology</i> , 2002, 42, 147-153.	1.9	28
60	Assessment of Treatment Techniques and Collimation in Conformal Stereotactic Radiosurgery and Radiotherapy. , 2000, , 206-206.		0
61	Impact of the filling status of the bladder and rectum on their integral dose distribution and the movement of the uterus in the treatment planning of gynaecological cancer. <i>Radiotherapy and Oncology</i> , 1999, 52, 29-34.	0.6	134
62	High-dose rate interstitial with external beam irradiation for localized prostate cancer – results of a prospective trial. <i>Radiotherapy and Oncology</i> , 1998, 48, 197-202.	0.6	113